Navigation Links
Pharmasset to Present at Deutsche Bank Healthcare Conference
Date:5/14/2009

condarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

        Pegasys(R) and Copegus(R) are registered trademarks of Roche.

        Contact
        Richard E. T. Smith, Ph.D.
        VP, Investor Relations and Corporate Communications
        richard.smith@pharmasset.com
        Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause ou
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Pharmasset to Present at Two Upcoming Investor Conferences
2. Pharmasset to Present at Two Upcoming Investor Conferences
3. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
4. Pharmasset to Webcast an Investor Event from the AASLD Meeting
5. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
6. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
7. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
8. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
9. Pharmassets Underwriters Release Shares from Lock-Up
10. Medco to Present at the Deutsche Bank 34th Annual Health Care Conference
11. Perforomist Inhalation Solution data to be presented at American Thoracic Society conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... In ... heart attack and stroke incidents are linked to testosterone replacement therapy announce an ... Conference is scheduled for July 9, 2015, according to court documents.* The testosterone ...
(Date:6/30/2015)... ... June 30, 2015 , ... The ... (D-MA) and Danny Davis (D-IL) for writing to the Department of Health and ... nation’s largest behavioral healthcare system, Universal Health Services (UHS).[1] CCHR is expanding its ...
(Date:6/30/2015)... ... June 30, 2015 , ... India Network Foundation ... Aetna, Inc. for its visitor health insurance plans that provides coverage for visitors to ... providers nationwide to enable visitors to obtain services from most experienced health care professional ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... D. Wagner, Chief Research and Strategy Officer at Predictive Analytics Reporting (PAR) Framework, ... National Science Foundation (NSF), will provide keynote addresses at the 2015 STEMtech conference ...
(Date:6/30/2015)... ... June 30, 2015 , ... Under ... protection at less thickness than any other padding in football. , Developed in ... and shock absorption, Gameday Armour is engineered with D3O protective polymer. This radical ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 2Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 3Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 5Health News:India Network Announces Accessibility of First Health PPO Nationwide Network for Visitor Health Insurance Plan Participants Effective July 1, 2015 2Health News:India Network Announces Accessibility of First Health PPO Nationwide Network for Visitor Health Insurance Plan Participants Effective July 1, 2015 3Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 2Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 3Health News:Under Armour Launches Advanced Gameday Armour® Max Protection System For The Gridiron 2
... Ranbaxy Laboratories and Cipla announced an alliance to ... had recently received Drug Controller General of India’s ... a unique dosage form of the broad-spectrum antibiotic. ... be around Rs 310 crore. //,Ciprofloxacin ...
... antioxidants, often as compounds known as flavonoids. It has ... levels of health-promoting flavonoids than apples or orange juice. ... are produced when oxygen burns glucose in cells to ... like DNA and proteins, setting the scene for heart ...
... There are many grueling and expensive options to explore for ... being Acupuncture. ,According to an article from the San ... may have been through the other options. They usually face ... born with a certain number of eggs, hundreds are lost ...
... fruits and vegetables, but don't forget whole grains, if ... disease and cancer, researchers say. Fruits and vegetables especially ... risk by about 32%. , According to a study ... of two to three slices of whole-grain bread each day were ...
... can keep lungs from deteriorating and reduce the risk ... of Ohahio, Dr.Margit Pelkon and collegues investigated the effects ... Finnish participants in four groups:// those who had never ... quit intermittently, and those who had never quit. ...
... the US suggest that acupuncture is at least as ... evidence on the safety of complementary and alternative medicine(CAM). ... of the first serious safety assessments on acupuncture. In ... agreed to record any adverse events occurring between June ...
Cached Medicine News:
(Date:6/30/2015)... , June 30, 2015 Dipexium ... stage pharmaceutical company focused on the development and ... the closing of its previously announced underwritten public ... underwriters also exercised their over-allotment option in full ... stock. The net proceeds to Dipexium ...
(Date:6/30/2015)... 30, 2015 Pulse Light Clinic in ... to Rosacea sufferers as part of their ongoing research into ... found effective for their Rosacea. The survey participants were aged ... men and 53% women. The results revealed some ... not consider or attempt to visit their GP for Rosacea ...
(Date:6/30/2015)... -- Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage biopharmaceutical ... announced that the Company will host its inaugural R&D ... pm EDT in New York City ... will present an overview of the Company,s pipeline programs, ... 2b clinical trials for the treatment of patients with ...
Breaking Medicine Technology:Dipexium Announces Closing of Public Offering of Common Stock 2Dipexium Announces Closing of Public Offering of Common Stock 384% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2
... , DENVER , Feb. 11 ... and marketer of diagnostic test kits, today filed its 2nd quarter ... the company,s revenues slightly declined during the quarter but slightly increased ... of the results highlighted by the report are as follows: , ...
... MOUNTAIN VIEW, Calif. , Feb. 11 Alexza Pharmaceuticals, ... & Drug Administration has accepted the AZ-004 NDA for filing and ... of October 11, 2010 .  Alexza filed the AZ-004 NDA ... for the rapid treatment of agitation in patients with schizophrenia or ...
Cached Medicine Technology:Corgenix Reports Second Quarter Fiscal 2010 Financial Results 2Corgenix Reports Second Quarter Fiscal 2010 Financial Results 3Corgenix Reports Second Quarter Fiscal 2010 Financial Results 4Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010 2Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010 3
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... Amvex offers a complete line ... heliox and CO 2 . They ... of calibrations to best suit your ... dials specific to the gas in ...
... Amvex offers a complete line ... heliox and CO 2 . They ... of calibrations to best suit your ... dials specific to the gas in ...
... Amvex offers a complete line of flowmeters, available ... are all available in a variety of calibrations to ... dials specific to the gas in use, the Amvex ... colors replace the U with I. For Power Take-Off ...
Medicine Products: